Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
This study has been terminated.
( Low accrual. )
Study NCT00561912 Information provided by M.D. Anderson Cancer Center
First Received on November 20, 2007. Last Updated on November 22, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Renal Cell Carcinoma
Additional conditions recognized in this trial
Carcinoma
Carcinoma, Renal Cell
More general conditions related to this trial
Adenocarcinoma
Kidney Diseases
Kidney Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
Decitabine
Interferon Alfa-2b
Additional drug interventions recognized in this trial
Azacitidine
Interferon Alfa-2a
Interferon-alpha
Interferons
Reaferon
More general drug interventions related to this trial
Adjuvants, Immunologic
Alcohol Deterrents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Eisai Inc.
Back to top of Main Content
